Embedded Files
DelveInsight’s “Hypertension Pipeline Insight, 2025” report delivers extensive information on over 80 companies and more than 100 pipeline drugs shaping the Hypertension treatment landscape. It encompasses detailed profiles of Hypertension pipeline drugs, spanning clinical and non-clinical stage products. Additionally, it evaluates Hypertension pipeline therapeutics based on product type, development stage, administration route, and molecule type. The report also spotlights inactive pipeline products in this field. Dive into DelveInsight’s thorough insights and remain at the forefront of comprehending the Hypertension Treatment Landscape @ Hypertension Pipeline Outlook
Key Highlights from the Hypertension Pipeline Report
November 25, 2025 — The United States has again earned a D+ grade for preterm birth in the 2025 March of Dimes Report Card, which has monitored national maternal and infant health since 2009 through indicators like preterm birth, prenatal care, infant and maternal mortality, and associated metrics. The nationwide preterm birth rate stays steady at 10.4%, with approximately 380,000 infants born prematurely in 2024—equating to one out of every ten births. Notable inequalities endure, with preterm birth rates for babies of Black mothers hitting 14.7%, roughly 1.5 times the national average, and those of Medicaid-covered mothers showing higher prematurity than privately insured ones (11.7% vs. 9.6%). Moreover, about one-quarter of expectant individuals (24.5%) missed first-trimester prenatal care, continuing a four-year downward trend.
On November 19, 2025, Apollo Therapeutics Ltd initiated the AP13CP02 study, a Phase 2, open-label, dose escalation trial to evaluate the safety and tolerability of multiple subcutaneous (SC) injections of APL-9796 in patients with PH. The trial will also examine APL-9796's efficacy in managing PH and check for the development of antibodies against the drug.
On November 19, 2025, Pfizer disclosed a study aimed at understanding the tolerability and effects of the investigational drug PF-07868489 in healthy adults and individuals with pulmonary arterial hypertension (PAH). This is an investigator- and participant-blinded, sponsor-open, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of PF-07868489 in healthy adult volunteers.
DelveInsight’s Hypertension pipeline report illustrates a vibrant sector with 80+ active entities advancing 100+ pipeline therapies for Hypertension management. Leading Hypertension firms include Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc, Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical, and others. Promising Hypertension Pipeline Therapies encompass Ramipril and hydrochlorothiazide, Liraglutide, Nebivolol, Metoprolol XL, Aliskiren and HCTZ, Bunazosin, Doxazosin, Valsartan, Losartan Potassium, and more.
Explore revolutionary advancements in Hypertension Therapies! Acquire deep knowledge of major clinical trials, novel drugs, and market prospects @ Hypertension Ongoing Clinical Trials Assessment
The Hypertension Pipeline Report offers a disease summary, pipeline overview, and therapeutic evaluation of prominent pipeline therapies in this area. It also emphasizes unmet needs related to hypertension.
Hypertension Overview
Hypertension, often referred to as high blood pressure, is a long-term health issue marked by increased arterial pressure, potentially resulting in severe complications if unmanaged. It is divided into primary hypertension, with no clear cause and gradual onset over years, and secondary hypertension, stemming from an underlying issue like kidney disease or hormonal imbalances.
Hypertension Emerging Drugs Profile
Seralutinib: Gossamer Bio
Seralutinib, created by Gossamer Bio, is an inhaled treatment for pulmonary arterial hypertension (PAH). It acts as an antagonist to multiple receptors, such as platelet-derived growth factor receptors (PDGFRα and PDGFRβ), colony-stimulating factor 1 receptor (CSF1R), and c-KIT. This multi-targeted strategy seeks to address inflammatory and proliferative processes driving pulmonary vascular remodeling in PAH. The drug is currently in Phase III development for Pulmonary Arterial Hypertension.
AD-209: Addpharma Inc.
AD-209 is an experimental medication from Addpharma Inc., aimed at Hypertension. It belongs to a wider portfolio of innovative treatments for conditions like hyperlipidemia and diabetes. The drug is presently in Phase III trials for Hypertension.
Zilebesiran: Alnylam Therapeutics
Zilebesiran is an investigational RNA interference (RNAi) therapy by Alnylam Therapeutics, focused on Hypertension. It targets the inhibition of angiotensinogen (AGT) synthesis, a vital component of the Renin-Angiotensin-Aldosterone System (RAAS) involved in blood pressure control. Using RNAi, it selectively diminishes AGT production in the liver, reducing angiotensin II levels—a strong vasoconstrictor linked to high blood pressure. This leads to prolonged blood pressure lowering. The drug is in Phase II development for Hypertension.
LAM-001: OrphAI Therapeutics
LAM-001 is an experimental inhaled version of sirolimus (rapamycin) from OrphAI Therapeutics, tailored for pulmonary hypertension (PH) and bronchiolitis obliterans syndrome (BOS), which can impair lung function and life quality. It is currently in Phase II trials for Pulmonary Hypertension.
HS135: 35Pharma Inc.
HS135 is an investigational agent by 35Pharma Inc., targeting pulmonary hypertension (PH) and associated cardiometabolic disorders. It is a multi-specific receptor ectodomain ligand trap that blocks activins and growth differentiation factors (GDFs), key contributors to these ailments. HS135 acts as a ligand trap to inhibit activin A and GDF-8, restoring balance in pathways linked to pulmonary hypertension and obesity-induced heart failure. The drug is in Phase I development for Pulmonary Arterial Hypertension.
Keep up with Hypertension pipeline trends! Discover essential updates on therapeutic breakthroughs and their implications for patients and the healthcare sector @ Hypertension Unmet Needs
The Hypertension Pipeline Report Delivers Insights into
The report shares comprehensive details on organizations advancing therapies for Hypertension, including the total therapies per company. It categorizes various therapeutic candidates into early, mid, and late development phases for Hypertension treatment. Companies are engaged in targeted drug development, with active and inactive (dormant or halted) initiatives. Drugs in development are classified by development phase, administration method, target receptor, monotherapy or combination approach, distinct mechanisms, and molecular structure. In-depth review of partnerships (corporate-corporate and corporate-academic), licensing deals, and funding for advancing the Hypertension market.
Hypertension Companies
Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc., Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical, and others.
The Hypertension pipeline report assesses pipeline drugs by Route of Administration. Products are grouped under routes like Oral, Intravenous, Subcutaneous, Parenteral, Topical.
Products are also classified by Molecule Types such as Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy.
Transform your grasp of the Hypertension Pipeline! Review the newest advancements in drug creation and clinical studies @ Hypertension Market Drivers and Barriers, and Future Perspectives
Scope of the Hypertension Pipeline Report
Coverage- Global
Hypertension Companies- Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc, Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical, and others.
Hypertension Pipeline Therapies- Ramipril and hydrochlorothiazide, Liraglutide, Nebivolol, Metoprolol XL, Aliskiren and HCTZ, Bunazosin, Doxazosin, Valsartan, Losartan Potassium, and others.
Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Cardiovascular Diseases Research–Access the Full Hypertension Pipeline Analysis Today! @ Hypertension Drugs and Companies
Table of Contents
Introduction
Executive Summary
Hypertension: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hypertension – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Seralutinib: Gossamer Bio
Mid Stage Products (Phase II)
Zilebesiran: Alnylam Therapeutics
Early Stage Products (Phase I)
HS135: 35Pharma Inc.
Preclinical and Discovery Stage Products
Drug name: Company name
Inactive Products
Hypertension Key Companies
Hypertension Key Products
Hypertension- Unmet Needs
Hypertension- Market Drivers and Barriers
Hypertension- Future Perspectives and Conclusion
Hypertension Analyst Views
Hypertension Key Companies
Appendix
About Us
DelveInsight is a premier healthcare-focused market research and consulting firm delivering high-quality market intelligence and analysis to guide strategic decisions. With a skilled team of industry specialists and profound expertise in life sciences and healthcare, we provide tailored research solutions and insights worldwide. Reach out for premium, precise, and timely intelligence to lead in the evolving landscape.
Contact Us
Contact Us
Kanishk
Page updated
Google Sites
Report abuse